Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06980636) titled 'A Trial of Shengmai Liquid for Long COVID Fatigue' on May 18.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Beijing University of Chinese Medicine

Condition: Long COVID Fatigue

Intervention: Drug: Shengmai Liquid

Recruitment Status: Not recruiting

Phase: Phase 4

Date of First Enrollment: June 1, 2025

Target Sample Size: 100

To know more, visit https://clinicaltrials.gov/ct2/show/NCT06980636

Disclaimer: Curated by HT Sy...